The challenges of tumor genetic diversity
Open Access
Abstract
The authors review and discuss the implications of genomic analyses documenting the diversity of tumors, both among patients and within individual tumors. Genetic diversity among solid tumors limits targeted therapies, because few mutations that drive tumors are both targetable and at high prevalence. Many more driver mutations and how they affect cellular signaling pathways must be identified if targeted therapy is to become widely useful. Genetic diversity within a tumor—intratumor genetic heterogeneity—makes the tumor a collection of subclones: related yet distinct cancers. Selection for pre‐existing, resistant subclones by conventional or targeted therapies may explain many treatment failures. Immune therapy faces the same fundamental challenges. Nevertheless, the processes that generate and maintain heterogeneity might provide novel therapeutic targets. Addressing both types of diversity requires genomic tumor analyses linked to detailed clinical data. The trend toward sequencing restricted cancer gene panels, however, limits the ability to discover new driver mutations and assess intratumor heterogeneity. Clinical data currently collected with genomic analyses often lack critical information, substantially limiting their use in understanding tumor diversity. Now that diversity among and within tumors can no longer be ignored, research and clinical practice must adapt to take diversity into account. Cancer 2017;123:917–27. © 2016 American Cancer Society.Keywords
Funding Information
- National Institute of Health (R01 DE022087)
- Head and Neck Cancer at The Ohio State University
- Bacardi Head and Neck Cancer Research Fund
This publication has 66 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Dynamics of targeted cancer therapyTrends in Molecular Medicine, 2012
- Intra-tumour heterogeneity: a looking glass for cancer?Nature Reviews Cancer, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel SequencingCancer Discovery, 2012
- Targeted enrichment of genomic DNA regions for next-generation sequencingBriefings in Functional Genomics, 2011
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategyJournal of Clinical Investigation, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Next-Generation DNA Sequencing MethodsAnnual Review of Genomics and Human Genetics, 2008
- Targeted cancer therapyNature, 2004